Key terms
About NEO
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NEO news
Feb 26
7:39am ET
NeoGenomics price target raised to $20 from $18 at Piper Sandler
Feb 24
10:06am ET
NeoGenomics Launches Performance-Based Stock Incentive Plan
Feb 22
12:15am ET
Buy Rating Affirmed for NeoGenomics Amidst Strong Growth and Strategic Market Positioning
Feb 21
5:13pm ET
NeoGenomics price target raised to $19 from $17 at Goldman Sachs
Feb 21
8:46am ET
NeoGenomics (NEO) Receives a Buy from Craig-Hallum
Feb 21
8:11am ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), NeoGenomics (NEO) and Ardelyx (ARDX)
Feb 21
7:20am ET
Analysts Conflicted on These Healthcare Names: NeoGenomics (NEO), Axsome Therapeutics (AXSM) and Medtronic (MDT)
Feb 21
7:19am ET
NeoGenomics price target raised to $23 from $21 at BTIG
Feb 21
7:17am ET
NeoGenomics reports Q4 non-GAAP EPS 3c, consensus (2c)
Feb 21
7:13am ET
NeoGenomics price target raised to $21 from $19 at TD Cowen
Feb 21
6:42am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Teladoc (TDOC) and NeoGenomics (NEO)
Feb 21
5:40am ET
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Bicycle Therapeutics (BCYC)
Feb 21
5:28am ET
NeoGenomics’ Solid Performance Tempered by Legal Risks: A Hold Rating Justified
Feb 20
11:05pm ET
NeoGenomics Earnings Beat with Upgraded Long-term Growth Forecast: Buy Rating Justified
Feb 20
4:09pm ET
NeoGenomics reports Q4 EPS (11c), consensus (2c)
Feb 18
11:50pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 07
5:40am ET
BTIG Reaffirms Their Buy Rating on NeoGenomics (NEO)
Jan 02
9:29am ET
BTIG Sticks to Their Buy Rating for NeoGenomics (NEO)
Jan 01
2:40am ET
Analysts’ Top Healthcare Picks: NeoGenomics (NEO), Cytokinetics (CYTK)
Dec 29
8:26am ET
NeoGenomics price target lowered to $19 from $22 at TD Cowen
Dec 29
7:05am ET
NeoGenomics price target lowered to $21 from $25 at BTIG
Dec 29
7:01am ET
Natera price target raised to $85 from $75 at BTIG
Dec 29
6:45am ET
Maintaining Hold on NeoGenomics: Legal Challenges Offset by Steady Growth Outlook
Dec 29
6:40am ET
NeoGenomics price target lowered to $18 from $19 at BofA
Dec 29
6:08am ET
Natera price target raised to $64 from $56 at Goldman Sachs
Dec 28
10:15pm ET
Buy Rating on NeoGenomics Amidst Growth and Market Leadership in Precision Oncology Diagnostics
Dec 28
8:45am ET
Maintaining Buy on NeoGenomics: Strong Fundamentals Amid RaDaR Setback
Dec 28
8:13am ET
NeoGenomics to appeal preliminary injunction by North Carolina court
Dec 28
5:18am ET
Natera wins preliminary injunction in NeoGenomics patent infringement lawsuit
Dec 05
8:24am ET
NeoGenomics receives first samples from SURVIVE trial
Dec 05
8:23am ET
NeoGenomics to present new data on RaDaR assay at SABCS
No recent press releases are available for NEO
NEO Financials
Key terms
Ad Feedback
NEO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NEO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
